EA201691529A1 - Гетероарильные амиды в качестве ингибиторов агрегации белков - Google Patents

Гетероарильные амиды в качестве ингибиторов агрегации белков

Info

Publication number
EA201691529A1
EA201691529A1 EA201691529A EA201691529A EA201691529A1 EA 201691529 A1 EA201691529 A1 EA 201691529A1 EA 201691529 A EA201691529 A EA 201691529A EA 201691529 A EA201691529 A EA 201691529A EA 201691529 A1 EA201691529 A1 EA 201691529A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
protein aggregation
methods
inhibitors
parkinson
Prior art date
Application number
EA201691529A
Other languages
English (en)
Other versions
EA032374B1 (ru
Inventor
Эмили М. Стокинг
Вольфганг ВРАЗИДЛО
Original Assignee
Нейропор Терапиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691529(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нейропор Терапиз, Инк. filed Critical Нейропор Терапиз, Инк.
Publication of EA201691529A1 publication Critical patent/EA201691529A1/ru
Publication of EA032374B1 publication Critical patent/EA032374B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к некоторым гетероарильным амидным соединениям, к фармацевтическим композициям, содержащим их, и способам их применения, в том числе и к способам предотвращения, инвертирования, замедления или ингибирования агрегации белков, а также к способам лечения заболеваний, которые связаны с агрегацией белков, в том числе нейродегенеративных заболеваний, таких как болезнь Паркинсона, болезнь Альцгеймера, болезнь телец Леви, болезнь Паркинсона с деменцией, лобно-височная деменция, болезни Хантингтона, амиотрофический боковой склероз и множественная системная атрофия и злокачественные опухоли и меланома.
EA201691529A 2014-01-29 2015-01-28 Гетероарильные амиды в качестве ингибиторов агрегации белков EA032374B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Publications (2)

Publication Number Publication Date
EA201691529A1 true EA201691529A1 (ru) 2017-01-30
EA032374B1 EA032374B1 (ru) 2019-05-31

Family

ID=52484559

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691529A EA032374B1 (ru) 2014-01-29 2015-01-28 Гетероарильные амиды в качестве ингибиторов агрегации белков

Country Status (37)

Country Link
US (3) US9738635B2 (ru)
EP (2) EP3348556B1 (ru)
JP (2) JP6619741B2 (ru)
KR (1) KR102383038B1 (ru)
CN (2) CN111039939B (ru)
AP (1) AP2016009347A0 (ru)
AU (1) AU2015211119B2 (ru)
BR (2) BR122018001892B1 (ru)
CA (1) CA2937967C (ru)
CL (1) CL2016001918A1 (ru)
CR (1) CR20160394A (ru)
CY (2) CY1120348T1 (ru)
DK (2) DK3348556T3 (ru)
EA (1) EA032374B1 (ru)
EC (1) ECSP16070327A (ru)
ES (2) ES2808978T3 (ru)
HK (1) HK1231470A1 (ru)
HR (2) HRP20180813T1 (ru)
HU (2) HUE050964T2 (ru)
IL (1) IL246987B (ru)
LT (2) LT3099684T (ru)
ME (1) ME03800B (ru)
MX (1) MX2016009896A (ru)
MY (1) MY187450A (ru)
NZ (1) NZ722487A (ru)
PE (1) PE20161393A1 (ru)
PH (1) PH12016501493A1 (ru)
PL (2) PL3348556T3 (ru)
PT (2) PT3099684T (ru)
RS (2) RS60547B1 (ru)
SA (1) SA516371579B1 (ru)
SG (1) SG11201606108RA (ru)
SI (2) SI3348556T1 (ru)
TR (1) TR201809440T4 (ru)
UA (1) UA118209C2 (ru)
WO (1) WO2015116663A1 (ru)
ZA (1) ZA201605246B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60547B1 (sr) 2014-01-29 2020-08-31 UCB Biopharma SRL Heteroaril amidi kao inhibitori proteinske agregacije
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN107625767A (zh) * 2016-11-25 2018-01-26 刘淑兰 一种治疗慢性盆腔炎的药物
MX2019008256A (es) 2017-01-26 2019-09-09 Ucb Biopharma Sprl Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
AU2018212436A1 (en) 2017-01-26 2019-07-25 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
ES2918048T3 (es) * 2017-01-26 2022-07-13 UCB Biopharma SRL Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
JP7283699B2 (ja) * 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
JP2020529432A (ja) 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. 微生物により誘発されるアミロイドの阻害剤
EP3703730A4 (en) * 2017-10-31 2022-01-12 Loma Linda University METHODS OF TREATMENT OF TRAUMATIC BRAIN DAMAGE
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
CN118488951A (zh) * 2021-12-27 2024-08-13 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2024094731A1 (en) * 2022-11-02 2024-05-10 Ac Immune Sa Novel compounds for the diagnosis of tdp-43 proteinopathies
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
US7504410B2 (en) * 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
EP1697371B1 (en) * 2003-12-19 2007-04-25 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
WO2006021884A2 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
JP2009505948A (ja) * 2005-07-11 2009-02-12 デブジェン エヌブイ キナーゼ阻害剤としてのアミド誘導体
CN101233119A (zh) * 2005-07-29 2008-07-30 4Sc股份有限公司 新型杂环NF-κB抑制剂
JP2009529555A (ja) * 2006-03-15 2009-08-20 ４エスツェー アクチェンゲゼルシャフト 新規複素環式ＮＦ−κＢ阻害薬
JP2010510177A (ja) * 2006-11-17 2010-04-02 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害を治療するための化合物および方法
EP2155226A4 (en) * 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING AGGREGATION OF PROTEINS AND METHODS OF MAKING AND USING SAME
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CA2776480A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
RU2012129882A (ru) 2009-12-16 2014-01-27 Нейропор Терапиз, Инк. Соединение
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
MX2014011615A (es) 2012-03-28 2015-01-19 Neuropore Therapies Inc Derivados de fenil-urea y fenil-carbamato como inhibidores de agregacion de proteina.
EP2872143B1 (en) * 2012-07-16 2017-12-13 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
RS60547B1 (sr) 2014-01-29 2020-08-31 UCB Biopharma SRL Heteroaril amidi kao inhibitori proteinske agregacije
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
MX2019008256A (es) 2017-01-26 2019-09-09 Ucb Biopharma Sprl Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
AU2018212436A1 (en) 2017-01-26 2019-07-25 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation

Also Published As

Publication number Publication date
HRP20201107T1 (hr) 2020-10-30
US20160207912A1 (en) 2016-07-21
CY1123374T1 (el) 2021-12-31
HUE040274T2 (hu) 2019-03-28
CR20160394A (es) 2016-11-01
PL3348556T3 (pl) 2020-11-02
AU2015211119A1 (en) 2016-08-11
CN106132960A (zh) 2016-11-16
CY1120348T1 (el) 2019-07-10
DK3099684T3 (en) 2018-07-16
HK1231470A1 (zh) 2017-12-22
ECSP16070327A (es) 2018-05-31
PT3099684T (pt) 2018-10-22
DK3348556T3 (da) 2020-08-03
JP6783900B2 (ja) 2020-11-11
MY187450A (en) 2021-09-22
US11078196B2 (en) 2021-08-03
SI3348556T1 (sl) 2020-10-30
KR102383038B1 (ko) 2022-04-05
EP3348556A1 (en) 2018-07-18
IL246987A0 (en) 2016-09-29
PT3348556T (pt) 2020-07-27
IL246987B (en) 2021-12-01
PE20161393A1 (es) 2017-01-08
SG11201606108RA (en) 2016-08-30
HRP20180813T1 (hr) 2018-07-27
ES2675301T3 (es) 2018-07-10
PH12016501493B1 (en) 2017-02-06
ES2808978T8 (es) 2021-03-22
CN111039939B (zh) 2023-09-19
KR20160113287A (ko) 2016-09-28
EP3099684A1 (en) 2016-12-07
US20180093979A1 (en) 2018-04-05
EP3348556B1 (en) 2020-04-29
RS60547B1 (sr) 2020-08-31
CN111039939A (zh) 2020-04-21
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
CL2016001918A1 (es) 2017-01-13
LT3348556T (lt) 2020-08-10
RS57533B1 (sr) 2018-10-31
JP2017505779A (ja) 2017-02-23
CA2937967A1 (en) 2015-08-06
PL3099684T3 (pl) 2018-09-28
LT3099684T (lt) 2018-06-25
CA2937967C (en) 2022-07-26
SI3099684T1 (en) 2018-08-31
NZ722487A (en) 2022-04-29
EA032374B1 (ru) 2019-05-31
US20190308965A1 (en) 2019-10-10
ES2808978T3 (es) 2021-03-02
MX2016009896A (es) 2017-01-11
BR122018001892B1 (pt) 2023-05-02
PH12016501493A1 (en) 2017-02-06
CN106132960B (zh) 2019-12-17
ZA201605246B (en) 2022-05-25
EP3099684B1 (en) 2018-04-04
AU2015211119A8 (en) 2016-12-15
HUE050964T2 (hu) 2021-01-28
EP3099684B8 (en) 2018-07-04
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
JP2019163321A (ja) 2019-09-26
TR201809440T4 (tr) 2018-07-23
AU2015211119B2 (en) 2019-05-30
JP6619741B2 (ja) 2019-12-11
ME03800B (me) 2021-04-20
BR112016017344B1 (pt) 2023-05-16
SA516371579B1 (ar) 2019-07-16
HRP20201107T8 (hr) 2020-12-11
AP2016009347A0 (en) 2016-07-31
BR112016017344A2 (pt) 2017-10-03
WO2015116663A8 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
EA201691529A1 (ru) Гетероарильные амиды в качестве ингибиторов агрегации белков
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201891526A3 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201592024A1 (ru) Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны
JO3458B1 (ar) 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
EA201991756A1 (ru) Бисгетероарильные производные в качестве модуляторов агрегации белков
EA201990400A1 (ru) Соединения и композиции и их применение
EA202090414A1 (ru) Соединения и их применение
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EA201990399A1 (ru) Соединения, композиции и их применение
EA201790315A1 (ru) Модуляторы x-рецепторов печени